Exact Sciences' 2024 sales grew 10% to $2.76 billion, exceeding estimates. New cancer tests, including Cologuard Plus, are ...

They’re non-invasive with none of the dreaded prep. But are recently approved home tests for colon cancer as effective as ...

Exact Sciences (EXAS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Michael ...

Reports preliminary FY24 revenue $2.76B, consensus $2.74B. Plans to launch three new cancer tests in 2025, namely Cologuard Plus, ...

Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the ...

The Alan B. Pearson Regional Cancer Center completed 299 free cancer screenings in 2024. The screenings included 250 skin ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/2.CDDzvsGh.js ...

Updated and document the member’s history annually including type and date of colon cancer screening tests, history of total colectomy, or history of colon cancer. **Note: A stool DNA (sDNA) with FIT ...

2 “After having the same discussion year after year with my doctor, he mentioned that there are these Cologuard® box tests for colorectal cancer screening,” Leigh Anne said. “I was so ...

ColoAlert, if approved in the U.S., may help rectify that lack of timely screening. After all, Mainz Biomed says its detection system is less invasive than ColoGuard, the leading at-home test in ...